Sudhakar Akul Yakkanti
Stanford Research Institute (SRI) International
Sudhakar Akul Yakkanti is the Associate Director/Senior Scientist at Center for Cancer & Metabolism, Cell Signaling Laboratory, Bioscience Division, Stanford Research Institute (SRI) International, Menlo Park, California. In addition he is the President of OMICS Organization 2012 on words. Earlier he was founder Director of Cell Signaling, Retinal and Tumor Angiogenesis Laboratory at Boys Town National Research Hospital, Omaha, NE, USA (2004-2012). He did his postdoctoral training at Harvard Medical School, Boston, MA, USA (2003). He received President’s fellowship (1992), GATE (1996) and CSIR (1997-2000) fellowships from Government of India. He received Mahindra & Mahindra Educational Award (2000) and Young Clinical Scientist Awards from Flight Attendant Medical Research Institute (FAMRI) in 2007 and 2010. He also received Bio-Bio Young Scientist Award from OMICS publishing group; Michael A. O’Connor Young Investigator Award; RO1 grant Award from NIH/NCI and Research Scholar Grant Award from ACS (2010). He is serving as AIBS/NIH-RO1 Grant reviewer for DT study section. He has published more than 40 research articles in several top journals including Science, Cancer Cell, JCI, Blood, PNAS, Gastroenterology, Cancer Research, JBC, IOVS, PLOS One etc. He is serving as an Editor-in- Chief, Executive Editor, Editor and Editorial board member of reputed journals and is serving as a reviewer for about 26 scientific journals including JCI, Blood, Circulation, Circulation Research, Cancer research, Clinical Cancer research etc. He was honored by giving a position as Honorable guest, Keynote Speaker, Session Chair, Co-chair and organizing committee member for several national and international conferences.
Extracellular matrix and Integrin Signaling, Biology and significance of type IV collagen derived angioinhibitors, Endogenous angioinhibitors role in Cancer and tumor microenvironment, Hypoxic tumorangiogenesis, Mechanism of endothelial apoptosis, Bioequivalence & Bioavailability of endogenous circulating angioinhibitors.